Local nasal immunotherapy in allergic rhinitis to <i>Parietaria</i>

Andri, L; Senna, Gianenrico; Betteli, C.; Givanni, S; Andri, G; Falagiani, P.; Lugo, G

doi:10.1111/j.1398-9995.1992.tb02061.x

Cited by 61 publications

(41 citation statements)

References 21 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, 21 studies are available for LNIT, and 14 of them were properly performed (43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54)(55)(56), Of these, 13 report a significant improvement of rhinitic symptoms. Furthermore, a reduction of the nasal reactivity and local immunologic response was found in some studies, while systemic immunologic changes were usually absent or equivocal: this may suggest that LNIT exerts its actions only on the target organ.…”

Section: Experimental Evidence: Clinical Efficacymentioning

confidence: 99%

Local immunotherapy: pharmacokinetics and efficacy

Passalacqua

Bagnasco

Mariani

et al. 1998

Allergy

Self Cite

View full text Add to dashboard Cite

Section: Experimental Evidence: Clinical Efficacymentioning

confidence: 99%

Local immunotherapy: pharmacokinetics and efficacy

Passalacqua

Bagnasco

Mariani

et al. 1998

Allergy

Self Cite

View full text Add to dashboard Cite

“…The first involved subcutaneous injections of an alginate-conjugated extract [24]. The second used nasal inhalations of an extract in macronized powder form [25]. Because demonstrations of efficacy for one allergen or one allergenic extract do not necessarily mean that efficacy will occur with other allergens or extracts there is a clear need for carefully controlled studies demonstrating such efficacy.…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy with Alpare® in patients with respiratory allergy to Parietaria pollen: a two year double‐blind placebo‐controlled study

D’Amato

Kordash

Liccardi

et al. 1995

Clin Experimental Allergy

View full text Add to dashboard Cite

Allergy to Parietaria judaica pollen causes significant morbidity in many areas of the world. In addition to rhinitis, patients who are allergic to this pollen have a high incidence of asthma. The pollinating season is long, making this particular allergy challenging for clinicians to treat. This study was designed to determine if immunotherapy with an alum adsorbed partially purified Parietaria extract (Alpare Parietaria) containing a targeted maintenance dose of 12,500 BUs was effective in decreasing rhinitis symptoms in patients allergic to Parietaria. Using a double-blind placebo-controlled technique 36 patients received placebo or active extract for 2 years. Twenty (11 placebo and nine active) completed the 2 year study. Efficacy of treatment was evaluated by determining changes in skin reactivity, visual analog scores, diary symptom scores and end of study assessments. Reactions were monitored as well. Skin-test suppression was marginally significant in the actively treated group after 1 year and showed even more significant suppression after the second year. Nasal block, rhinorrhoea and sneezing all were significantly decreased in the active group. The nasal provocation test did not show a significant change after 1 year, in either group, but after 2 years of treatment the active group did show significant improvement. Although almost all patients in the actively treated group experienced local reactions, the incidence of systemic reactions was not different between the two groups. In conclusion, immunotherapy with this extract at this dose was effective in ameliorated rhinitis symptoms in patients allergic to Parietaria judaica.

show abstract

“…On the same topic, Andri et al [19] showed that LNIT using an extract in macronized powder form reduced drug consumption in allergic rhinitis to Parietaria. LNIT with aqueous ragweed extract was clinically effective, with a dose-relation [20][21][22][23].…”

Section: Discussionmentioning

confidence: 99%

A double‐blind, placebo‐controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen

D’Amato

Lobefalo

Liccardi

et al. 1995

Clin Experimental Allergy

View full text Add to dashboard Cite

We assessed the efficacy and safety of local nasal immunotherapy (LNIT) using an extract in macronized powder form of Parietaria pollen, a very important allergenic plant in the Mediterranean and other parts of the world. Twenty-six patients aged 13-37 years, with seasonal allergic rhinitis to this pollen, were enrolled in a double-blind placebo-controlled trial, carried out from autumn 1991 to the end of June 1992. They were selected on the basis of a positive skin-prick test, radioallergosorbent test (RAST) and intranasal challenge to Parietaria antigen. Patients were randomly divided into two groups of 13; the first group was given Parietaria antigen, and the second placebo. We recorded mean weekly symptom scores and drug consumption for 17 weeks during the pollen season in the year 1992, and specific serum-IgE and IgG levels. Three patients in the active group withdrew from the study because of bronchial symptoms. A significant difference was observed in mean weekly nasal symptom scores, in drug consumption and in specific nasal threshold to Parietaria allergenic extract in the treated and control groups. No difference was observed in serum IgE and IgG levels. Serum IgE levels rose significantly only in the control group after the pollen season. This study indicates that LNIT may be a useful alternative to traditional subcutaneous immunotherapy in patients with allergic rhinitis.

show abstract

Local nasal immunotherapy in allergic rhinitis to Parietaria

Cited by 61 publications

References 21 publications

Local immunotherapy: pharmacokinetics and efficacy

Local immunotherapy: pharmacokinetics and efficacy

Immunotherapy with Alpare® in patients with respiratory allergy to Parietaria pollen: a two year double‐blind placebo‐controlled study

A double‐blind, placebo‐controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen

Contact Info

Product

Resources

About